FDA considering petition to protect biologic medications’ patents
The opening salvo fired by Abbott Laboratories could be the start of an interesting legal battle between pharmaceutical companies and generic manufacturers over biologic medicationsmedicines such as insulin or vaccines that are created through biological processes, not chemical synthesis.
By Julie BeckApril 22, 2013
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters.
Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss.
Tailored just for you. In your inbox. Every day.